Biomarker ID | 807 |
PMID | 22078333 |
Year | 2012 |
Biomarker | %p2PSA |
Biomarker Basis | Concentration Based (pg/ml) |
Biomolecule | Protein |
Source | Blood |
Subjects | Humans |
Regulation | Upregulated in Gleason Score ≥7 |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 3.154 (95% CI: 2.048–4.856); Multivariate: 3.485 (95% CI: 2.140–5.675); |
Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | Gleason Score ≥7 and Gleason Score <7 |
Type of Biomarker | Prognostic |
Cohort | 350 patients with prostate cancer were chosen. (n= 317) GS ≥ 7 and (n= 33) GS>7 |
Senstivity | 91.9 % (95% CI: 88.0–94.9) |
Specificity | 24.7 % (95% CI:16.2–35.0) |
AUC | 0.704 |
Accuracy | NA |
Level Of Significance | p<0.0001 |
Method Used | UniCel DxI800 Immunoassay System analyser (Beckman Coulter Inc., Brea, CA, USA) |
Clinical | No |
Remarks | Sensitivity, Specificity calculated at 3 different criterions |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | KLK3 |